Methotrexate therapy in polymyositis

75Citations
Citations of this article
17Readers
Mendeley users who have this article in their library.

Abstract

5 of 16 patients with polymyositis, whose disease could not be controlled with corticosteroids alone, received Methotrexate therapy. 4 had pure polymyositis while one had myositis associated with systemic sclerosis. As a group, they demonstrated, clinically and chemically, more severe muscle disease than those requiring steroids alone. 3 patients clearly responded to the drug, but toxicity was a significant limiting factor. The most serious complication, namely Methotrexate pneumonitis, observed in two patients receiving oral dosage, contributed to death in one. Methotrexate therapy, while a useful adjunct in the steroid refractory patient, is highly toxic, especially when given orally, and must be used with caution.

Cite

CITATION STYLE

APA

Arnett, F. C., Whelton, J. C., Zizic, T. M., & Stevens, M. B. (1973). Methotrexate therapy in polymyositis. Annals of the Rheumatic Diseases, 32(6), 536–546. https://doi.org/10.1136/ard.32.6.536

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free